3 documents found, page 1 of 1
NIS expression in thyroid tumors, relation with prognosis clinicopathological a...
Tavares, C; Coelho, MJ; Eloy, C; Melo, M; Rocha, AG; Pestana, A; Batista, R; Ferreira, LB; Rios, E; Selmi-Ruby, S; Cavadas, B; Pereira, LThyroid cancer therapy is based on surgery followed by radioiodine treatment. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS) (codified by the SLC5A5 gene), that is functional only when targeted to the cell membrane. We aimed to evaluate if NIS expression in thyroid primary tumors would be helpful in predicting tumor behavior, response to therapy and prognosis. NIS ...
mTOR pathway in papillary thyroid carcinoma: Different contributions of mTORC1 ...
Tavares, C; Eloy, C; Melo, M; Rocha, AG; Pestana, A; Batista, R; Ferreira, LB; Rios, E; Sobrinho-Simões, M; Soares, PThe mammalian target of rapamycin (mTOR) pathway is overactivated in thyroid cancer (TC). We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features. The distinct behavior...
Frequency of TERT promoter mutations in human cancers
Vinagre, J; Almeida, A; Pópulo, H; Batista, R; Lyra, J; Pinto, V; Coelho, R; Celestino, R; Prazeres, H; Lima, L; Melo, M; Rocha, AG; Preto, A; Castro, PReactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring tog...